Novakand

Novakand is a clinical-stage biotechnology company focused on the development of transformative therapies for rare kidney diseases, specifically targeting IgA Nephropathy (IgAN). Founded in 2023 by former executives from Calliditas Therapeutics, the company brings deep expertise in the renal and orphan drug sectors. Its lead program, NVK-001, is a dual endothelin and angiotensin receptor antagonist (DEARA) designed to address the complex pathophysiology of glomerular diseases. By inhibiting both the endothelin A and angiotensin II type 1 receptors, NVK-001 aims to significantly reduce proteinuria and preserve long-term renal function. Novakand is currently advancing its clinical pipeline to provide new treatment options for patients with high unmet needs in the nephrology space. The company is headquartered in Yardley, Pennsylvania, and operates as a private biopharmaceutical entity.